Recce Pharmaceuticals to be Granted New Anti-Viral Patent in Australia for RECCE® Anti-Infectives
April 11, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, April 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
Recce Pharmaceuticals Receives Further A$973,144 Research and Development (R&D) Advance
April 06, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, April 06, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals Announces RECCE® Trademark Registered in Hong Kong, Strengthening Global IP Portfolio
February 03, 2023 07:59 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced...
Recce Pharmaceuticals Receives A$6.21 Million from Research and Development (R&D) Rebate Payments
January 27, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, is pleased to...
Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives
January 11, 2023 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
Recce Pharmaceuticals Establishes Anti-Infective Research Unit at Murdoch Children’s Research Institute
December 19, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Recce’s new Anti-Infective Research Unit located within Murdoch Children's world-leading research facilities – internationally recognized for medical research breakthroughsFit-for-purpose...
Recce Pharmaceuticals Receives Ethics Approval to Start Phase 1/2 Study Evaluating RECCE® 327 in Patients with Diabetic Foot Infections
December 12, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Phase 1/2 trial of RECCE® 327 (R327) is approved to start at the South West Sydney Limb Preservation and Wound Research Unit, located at the Ingham Institute of Medical ResearchStudy will...
Recce Pharmaceuticals Announces Preclinical SARS-CoV-2 Study Update
October 18, 2022 08:11 ET
|
Recce Pharmaceuticals
Highlights: RECCE® 327 (R327) was shown to significantly reduce SARS-CoV-2 levels in hamsters, the gold-standard in COVID-19 preclinical animal modelsNew patents lodged supporting anti-infective...
Recce Pharmaceuticals Announces Expansion and Acceleration of Clinical Programs
October 03, 2022 08:00 ET
|
Recce Pharmaceuticals
Highlights: Phase 1 safety and tolerability study of RECCE® 327 (R327) advancing to a Phase 1b/2a multi-dose and sepsis efficacy studyInitiating two new Phase 2 trials of R327 for the treatment of...
Recce Pharmaceuticals Appoints Alistair McKeough to its Board of Directors
September 07, 2022 08:00 ET
|
Recce Pharmaceuticals
SYDNEY, Australia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company) is pleased to announce the appointment of Alistair McKeough to its Board of...